DEVELOPMENT OF A NOVEL TARGETED RADIOTHERAPEUTIC FOR THE TREATMENT OF PEDIATRIC HIGH-GRADE GLIOMA (HGG) AND EPENDYMOMA
$2,985,093FY2024Defense Health AgencyDOD
Plus Therapeutics, Inc., San Diego CA
Investigators
View source on USAspending →DEVELOPMENT OF A NOVEL TARGETED RADIOTHERAPEUTIC FOR THE TREATMENT OF PEDIATRIC HIGH-GRADE GLIOMA (HGG) AND EPENDYMOMA · GrantIndex